Investment from Sandwater, HealthCap, and Tesi will enhance supply chain,

来自Sandwater、HealthCap和Tesi的投资将增强供应链，

customer support, and R&D

客户支持以及研发

HELSINKI and JACKSONVILLE, Fla.

赫尔辛基和佛罗里达州杰克逊维尔

,

，

July 6, 2026

2026年7月6日

/PRNewswire/ --

/美通社/ --

CurifyLabs

CurifyLabs

, a health technology company transforming how personalized medicines are made, today announced the closing of a $14 million Series A funding round. The round was co-led by

，一家正在变革个性化药物制造方式的健康科技公司，今日宣布完成1400万美元的A轮融资。本轮融资由

Sandwater

沙水

and

和

HealthCap

健康帽

, with participation from

，参与方包括

Tesi

论文

(Finnish Industry Investment Ltd.) and existing investors, including

（芬兰工业投资有限公司）及现有投资者，包括

Lifeline Ventures

生命线创投

. U.S. customers and employees also participated in the round.

美国客户和员工也参与了本轮。

Proceeds will be used to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation.

所得款项将用于扩大美国业务、加强供应链基础设施、提升客户支持以及加速产品创新。

CurifyLabs' Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate the preparation of personalized medications. With advanced quality control processes built in, the CSS produces tailored doses and dosage forms with greater precision and speed than the manual processes typically used in pharmacies today..

CurifyLabs 的复合制剂系统解决方案（CSS）融合了专有软件、符合药品生产质量管理规范（GMP）生产的辅料基质以及先进的3D打印技术，实现了个性化药物制备的自动化。凭借内置的高级质量控制流程，CSS 能够以比当今药房通常采用的手工流程更高的精度和速度，生产定制化的剂量和剂型。

Pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses every day. As the company continues to scale, it will invest in its supply chain to ensure its growing network of pharmacy partners has what it needs, when it needs it.

美国21个州以及欧洲各地的药店均采用CurifyLabs的技术，每天配制和分发数千剂药物。随着公司持续扩大规模，它将加大对供应链的投入，以确保其不断扩大的药店合作伙伴网络能够在需要时获得所需资源。

'Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way,' said Morten E. Iversen, partner at Sandwater. 'CurifyLabs has built something rare — technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on.

“个性化医疗是医疗保健领域最重要的前沿方向之一，能够改善患者疗效，并正经历稳健增长。我们正在帮助更多药房以更安全、更高效的方式提供个性化医疗，”Sandwater合伙人Morten E. Iversen表示。“CurifyLabs打造了一种罕见的技术，它将临床严谨性与繁忙药房团队所依赖的速度和精准度相结合。”

We are excited to support their rapid growth in the U.S. and beyond.'.

我们很高兴能够支持他们在美国及其他地区的快速发展。

'We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution,' said

“在近三十年的时间里，我们已支持超过136家生命科学公司，而最优秀的创始人之所以脱颖而出，在于他们能够将深厚的科学素养与实际的执行能力相结合。”

Daniel Karsberg

丹尼尔·卡斯伯格

, partner at HealthCap. 'The CurifyLabs team has done exactly that.'

HealthCap的合伙人表示：“CurifyLabs团队正是这样做的。”

'CurifyLabs is the kind of company we want to support — innovative, globally ambitious, and built on deep scientific expertise,' said

“CurifyLabs 正是我们希望支持的那类公司——富有创新精神、具备全球雄心，并建立在深厚的科学专业知识基础之上。”

Joni Karsikas

约尼·卡尔西卡斯

, Investment Director at Tesi. 'Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage.'

Tesi 的投资总监表示：“他们在美国市场的增长进一步证明，芬兰的健康科技能够在全球舞台上竞争并取胜。”

'This investment reflects the conviction our partners have in what we're building,' said

“这项投资反映了我们的合作伙伴对我们正在构建的事业所抱有的坚定信念，”

Charlotta Topelius

夏洛塔·托佩利乌斯

, CEO and Founder, CurifyLabs. 'We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.'

CurifyLabs 首席执行官兼创始人表示：“我们为临床严谨性、产品质量和客户支持设定了高标准，而此次融资为我们提供了进一步提升这些标准的资源。”

The funding will support ongoing development of the CurifyLabs platform, including its most recent product, the PharmaPrinter Aurum, which compounds up to nine times faster than manual processes. CurifyLabs' technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards for non-sterile compounding..

这笔资金将支持CurifyLabs平台的持续开发，包括其最新产品PharmaPrinter Aurum，该产品的配药速度比手工流程快多达九倍。CurifyLabs的技术已获得ISO 13485认证，并依据美国食品药品监督管理局（FDA）503A/503B非无菌配药标准进行设计。

About CurifyLabs

关于 CurifyLabs

Founded in 2021, CurifyLabs is transforming how personalized medicines are made. Its Compounding System Solution combines proprietary software, GMP-manufactured excipients, and advanced 3D printing technology to bring consistency, safety, and speed to personalized compounding. The company serves compounding pharmacies across 21 U.S.

CurifyLabs 成立于2021年，正在变革个性化药物的制造方式。其复方制剂系统解决方案结合了专有软件、符合药品生产质量管理规范（GMP）生产的辅料以及先进的3D打印技术，为个性化复方制剂带来一致性、安全性和速度。该公司服务于美国21个州的复方制剂药房。

states, where its technology is used to compound and dispense thousands of doses every day. CurifyLabs partners with pharmacies to help deliver precise, patient-specific therapies efficiently and reliably. For more information, visit.

州，其技术每天用于配制和分发数千剂药物。CurifyLabs 与药店合作，帮助高效、可靠地提供精确的个性化患者治疗。欲了解更多信息，请访问。

curifylabs.com

curifylabs.com

.

。

About Sandwater

关于Sandwater

Sandwater invests in the commercialization of deep tech and impact-driven companies addressing critical challenges across energy, resource efficiency, robotics/AI and health. We partner with exceptional founders and we provide conviction, competence and capital. Visit sandwater.com to learn more. We invest from late seed through Series B across the Nordics and Northern Europe..

Sandwater 致力于投资深科技及具有社会影响力的公司，推动其商业化进程，以应对能源、资源效率、机器人/人工智能和健康领域的关键挑战。我们与杰出的创始人携手合作，提供坚定的信念、专业的能力以及充足的资本。请访问 sandwater.com 了解更多信息。我们的投资阶段涵盖从种子轮后期到 B 轮，地域范围遍及北欧及北欧地区。

About HealthCap

关于 HealthCap

HealthCap is a European venture capital firm investing exclusively in life sciences. Founded in 1996 and based in Stockholm and Lausanne, the firm has raised more than €1.5 billion across ten funds and backed more than 36 companies globally.

HealthCap 是一家专注于生命科学领域的欧洲风险投资公司。该公司成立于1996年，总部位于斯德哥尔摩和洛桑，已在十只基金中募集超过15亿欧元，并在全球范围内支持了36多家企业。

About Tesi

关于泰西

Tesi (Finnish Industry Investment Ltd.) is a state-owned Finnish investment company investing on market terms in venture capital and private equity funds and directly in growth companies. Tesi's mission is to develop Finland's investment market and promote economic growth.

Tesi（芬兰工业投资有限公司）是一家芬兰国有投资公司，按市场条件对风险投资和私募股权基金进行投资，并直接投资于成长型企业。Tesi 的使命是发展芬兰的投资市场并促进经济增长。

SOURCE CurifyLabs

来源：CurifyLabs

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

请求演示